Errata - English

Line 16 of Analysis: Change
Calculate the percentage of any individual unspecified impurity
to:
Calculate the percentage of any other individual impurity
AND
Line 20 of Analysis: Change
r_U = peak response of any individual unspecified impurity
to:
r_U = peak response of any other individual impurity

Line 2 of USP Ciprofloxacin Ethylenediamine Analog RS: Change
7-(2-Aminoethylamino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid.
C₁₅H₁₆FN₃O₃ 305.30
to:
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[(2-aminoethyl)amino]-3-quinolinecarboxylic acid hydrochloride.
C₁₅H₁₆FN₃O₃ · HCl 341.77

Line 2 of USP Ciprofloxacin Ethylenediamine Analog RS: Change
7-(2-Aminoethylamino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid.
C₁₅H₁₆FN₃O₃ 305.30
to:
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[(2-aminoethyl)amino]-3-quinolinecarboxylic acid hydrochloride.
C₁₅H₁₆FN₃O₃ · HCl 341.77

Line 1 of Physicochemical Tests/Acidity or Alkalinity/BRP indicator solution: Change
1.0 mg/mL of bromophenol blue,
to:
1.0 mg/mL of bromothymol blue,
AND
Line 3 of Plastic Additives/Polyethylene, Cyclic Olefins, and Polypropylene/Phenolic Antioxidants/Test B: Change
tris(2,4-di-tert-butylphenyl) phosphate;
to:
tris(2,4-di-tert-butylphenyl) phosphite;
AND
Line 1 of Plastic Additives/Polyethylene, Cyclic Olefins, and Polypropylene/Phenolic Antioxidants/Test C/Mobile phase: Change
(55:45:5, v/v/v)
to:
(50:45:5, v/v/v)
AND
Line 1 of Plastic Additives/Polyethylene, Cyclic Olefins, and Polypropylene/Nonphenolic Antioxidants/Chromatographic system/Application: Change
20 µL of Sample solution S10, reference solution (o) and the reference solutions corresponding to
to:
20 µL of Sample solution S10 and the reference solutions corresponding to
AND
Line 2 of Plastic Additives/Plasticized Polyvinyl Chloride/USP Reference Standards <11>/USP Plastic Additive 05 RS: Change
Tris(2,4-di-tert-butylphenyl) phosphate.
to:
Tris(2,4-di-tert-butylphenyl) phosphite.  

Line 10 of Analysis: Change
Result = (C/C_U) × [M_r/(3 × A_r)] × 100
to:
Result = C × 100/C_U
AND
Line 13 of Analysis: Change
C_U = nominal concentration, based on the Assay value, of potassium citrate monohydrate in the Sample solution (µg/mL)
M_r = molecular weight of potassium citrate monohydrate, 324.41
A_r = atomic weight of potassium, 39.10
to:
C_U = concentration of potassium citrate anhydrous (C₆H₅K₃O₇) in the Sample solution calculated from the Assay value of potassium citrate monohydrate (C₆H₅K₃O₇ · H₂O) (µg/mL)

Line 2 of USP Travoprost Related Compound A RS: Change
(5Z,13E)-(9S,11R,15R)-9,11,15-Trihydroxy-16-(m-trifluoromethylphenoxy)-17,18,19,20-tetranor-5,13-prostadienoic acid.
to:
(5Z,13E)-(9S,11R,15R)-9,11,15-Trihydroxy-16-(m-trifluoromethylphenoxy)-17,18,19,20-tetranor-5,13-prostadienoic acid
or
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-{(R,E)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl}cyclopentyl)hept-5-enoic acid.

Line 7 of Analysis: Change
Result = (r_U/r_S) × (C/W) × (V/D) × U × (100/L)
to:
Result = (r_U/r_S) × (C/W) × D × U × (100/L)
AND
Line 16 of the Analysis: Delete
V = volume of the Sample solution (mL)

Line 2 of first reference: Delete
http://www.acoem.org/Reproductive_Developmental_Hazard_Management.aspx.
AND
Line 2 of second reference: Delete
http://www.asco.org/advocacy/worker-safety-when-handling-hazardous-drugs-focus-statement-oncology-societies.

Line 5 of Type A1 (formerly, Type A): Change
radionucleotides
to:
radionuclides
AND
Line 5 of Type A2 (formerly, Type B3): Change
radionucleotides
to:
radionuclides
AND
Line 5 of Type B1: Change
radionucleotides
to:
radionuclides
AND
Line 5 of Type B2 (total exhaust): Change
radionucleotides
to:
radionuclides

USP Oxymetazoline Related Compound A RS: Change
N-(2-Aminoethyl)-2-[4-(tert-butyl)-3-hydroxy-2,6-dimethylphenyl]acetamide.
C₁₆H₂₆N₂O₂ 278.39
to:
N-(2-Aminoethyl)-2-[4-(tert-butyl)-3-hydroxy-2,6-dimethylphenyl]acetamide hydrochloride.
C₁₆H₂₆N₂O₂ · HCl 314.85

Line 2 of USP Perindopril Related Compound A RS: Change
(2S,3aS,7aS)-Octahydro-1H-indole-2-carboxylic acid hydrochloride.
C₁₇H₂₈N₂O₅ · HCl 205.68
to:
(2S,3aS,7aS)-Octahydro-1H-indole-2-carboxylic acid.
C₉H₁₅NO₂ 169.22

Line 2 of USP Desloratadine Related Compound B RS: Change
8-Chloro-11-(1,2,3,6-tetrahydropyridin-4-yl)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine.
C₁₉H₁₉ClN₂ 310.82
to:
8-Chloro-11-(1,2,3,6-tetrahydropyridin-4-yl)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine hydrochloride.
C₁₉H₂₀Cl₂N₂ 347.28

Line 2 of USP Granisetron Related Compound B RS: Change
(N-[(1R,3r,5)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide).
to:
(N-[(1R,3r,5S)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide).
AND
Line 2 of USP Granisetron Related Compound E RS: Change
((1R,3rS,5S)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine, acetate salt).
to:
((1R,3r,5S)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine, acetate salt).

Footnote k: Change
4-(4′-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate.
to:
4-(3′-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate.
AND
Footnote l: Change
4-(3′-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate.
to:
4-(4′-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate.

Line 4 of USP Ketorolac Related Compound A RS: Change
358.15
to:
358.39
AND
Line 3 of USP Ketorolac Related Compound B RS: Change
227.09
to:
227.26
AND
Line 3 of USP Ketorolac Related Compound C RS: Change
225.09
to:
225.24
AND
Line 3 of USP Ketorolac Related Compound D: Change
211.1
to:
211.3

Line 2 of USP Lovastatin Related Compound A RS: Change
[Dihydro-lovastatin][butanoic acid, 2-methyl-, 1,2,3,4,4a,7,8,8a-octahydro-3,7-dimethyl-8-[2(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1α(R*),3α,7β,8β(2S*,4S*),-8αβ]]]-.
to:
(1S,3S,4aR,7S,8S,8aS)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl (S)-2-methylbutanoate.

Line 6 of Analysis: Change
Result = (r_U/r_S) × (C_U/C_S) × 100
to:
Result = (r_U/r_S) × (C_S/C_U) × 100

Line 5: Change
Result = (r_U/r_S) × (C_S/C_U) × (M_r1/M_r2) × 100
to:
Result = (r_U/r_S) × (C_S/C_U)× 100
AND
Delete the variable definitions for M_r1 and M_r2.